Revenue and Net Income Gains Cap Strongest
Performance in a Decade
IntriCon Corporation (NASDAQ: IIN), a designer,
developer, manufacturer and distributor of miniature and
micro-miniature body-worn devices, today announced financial
results for its fourth quarter ended December 31, 2014.
Fourth-Quarter Highlights:
- Net sales of $16.5 million rose 10
percent over the prior-year period;
- Gross margins of 27.1 percent increased
from 25.5 percent;
- IntriCon achieved EPS of $0.06, up
significantly from an EPS loss of $(0.25) in the prior-year
period;
- The company’s value hearing health
business posted strong results, with revenues rising 31
percent;
- The company reduced bank debt by $2.0
million from 2013 year end;
- IntriCon secured CE (Conformité
Européenne) Mark approval allowing it to directly pursue
significant value hearing health opportunities throughout Europe;
and
- The company entered into a distribution
agreement with the United Kingdom’s PC Werth Ltd which allows
IntriCon to be a main supplier to the National Health Service (NHS)
Supply Chain’s National Framework.
Financial ResultsFor the 2014 fourth quarter, the company
reported net sales of $16.5 million, up from $15.0 million in the
prior-year period. IntriCon posted net income of $360,000, or $0.06
per diluted share, compared to a net loss of $(1.4) million, or
$(0.25) per diluted share, for the 2013 fourth quarter. Included in
the 2014 fourth-quarter results was a one-time $165,000, or $0.03
per diluted share, foreign tax expense charge. Included in 2013
fourth-quarter results was a net loss from discontinued operations
of $(1.6) million, or $(0.27) per diluted share.
“We are pleased to report continued strength, with double-digit,
top- and bottom-line growth for the fourth consecutive quarter,”
said Mark S. Gorder, president and chief executive officer of
IntriCon. “Our fourth-quarter results capped off the strongest year
for IntriCon from a net sales, gross margin and profitability
perspective, since the Selas restructuring nearly a decade ago. Our
strategy of developing partnerships with key value hearing health
and medical customers, and concentrating on our highest potential
opportunities in value hearing health and the medical biotelemetry
market is taking hold, as evidenced by our recent announcement of
the PC Werth contract.”
Gross profit margins grew to 27.1 percent from 25.5 percent in
the prior-year fourth quarter. The gains stemmed primarily from
volume increases and cost reductions achieved from the company’s
previously disclosed global restructuring plan.
Full-Year ResultsFor the 2014 full year, IntriCon
reported higher net sales of $68.3 million and net income of $2.2
million, or $0.37 per diluted share. This compares to 2013 annual
net sales of $53.0 million and a net loss of $(6.2) million, or
$(1.08) per diluted share. Net income from continuing operations
for the 2014 twelve-months was $2.5 million, or $0.42 per diluted
share, with a discontinued operations net loss of $(270,000), or
$(0.04) per diluted share. The 2013 annual results included a loss
from continuing operations of $(2.3) million, or $(0.40) per
diluted share, and a discontinued operations net loss of $(3.9)
million, or $(0.68) per diluted share.
Gross profit margins increased to 27.1 percent from 23.0 percent
for the full year 2013. Again, the improvement was primarily due to
volume increases and cost reductions.
Business UpdateHearing health sales grew during the
fourth quarter, rising 31 percent from the prior-year quarter,
primarily due to initial gains on targeted value hearing health
initiatives, including value hearing aids, personal sound amplifier
products (PSAP) and assistive listening devices.
Said Gorder, “We continue to make significant strides in the
hearing health market as demonstrated by the PC Werth partnership.
As we’ve previously noted, within the conventional hearing health
channel, industry growth and penetration rate continues to be
stagnated by high device costs, distribution inefficiencies and
retail consolidation. These factors, along with the rapidly growing
aging population, have created a need for an outcomes-based hearing
health model. To capitalize on this opportunity, we are
concentrating our efforts on significant prospective partnerships
and customers, and are aggressively pursuing the value hearing aid
and PSAP channels.”
PC Werth, through its partnership with IntriCon, has been
appointed one of the main suppliers to the NHS Supply Chain's
National Framework. The NHS is the largest purchaser of hearing
aids in the world, supplying an estimated 1.2 million hearing aids
annually. Under the agreement, PC Werth will distribute IntriCon
hearing aid products under the Kamplex brand name. PC Werth will
provide the required marketing, selling, training and service
support. IntriCon is currently working on product approval with the
NHS Audiology Supplies Group and anticipates having product
approved and available for sale in the first half of 2015.
Sales in IntriCon’s medical business declined 9 percent in the
2014 fourth quarter compared to the year-ago period, primarily
driven by an anticipated reduction in sales to IntriCon’s largest
customer, Medtronic. To support Medtronic’s MiniMed 530G insulin
pump launch in late 2013, IntriCon built and sold significant
inventory from the fourth quarter of 2013 through the first half of
2014. While the company has satisfied the initial launch volume
requirements, IntriCon anticipates sequential Medtronic revenue
growth in the 2015 first quarter and throughout 2015.
Fourth-quarter 2014 professional audio communication sales rose
41 percent from the prior-year period. During the quarter, the
company completed the final delivery on a significant contract with
the Singapore government to provide technically advanced headsets
worn in military applications. IntriCon will continue to leverage
its core technologies in professional audio communication to
support existing customers, as well as seek related hearing health
and medical product opportunities.
Looking AheadConcluded Gorder, “2014 was a very
successful year. We posted the strongest revenue and earnings in a
decade, completed our restructuring of the business and
importantly, made great strides in establishing our infrastructure
to drive growth in our value hearing health business. As we carry
this positive momentum into 2015, we anticipate higher sales for
the full year, with our first-quarter revenue consistent with our
2014 fourth quarter. Strategically, as we look to the future, we
will maintain our focus on aggressively expanding our value hearing
health reach and pursuing opportunities in value hearing health and
medical biotelemetry.”
Conference Call TodayAs previously announced, the company
will hold an investment community conference call today, Tuesday,
February 17, 2015, beginning at 4 p.m. CT. Mark Gorder, president
and chief executive officer, and Scott Longval, chief financial
officer, will review fourth-quarter performance and discuss the
company’s strategies. To join the conference call, dial:
1-888-438-5448 and provide the conference ID number 5633695 to the
operator.
A replay of the conference call will be available three hours
after the call ends through 7 p.m. CT on Tuesday, March 3, 2015. To
access the replay, dial 1-888-203-1112 and enter passcode:
5633695.
About IntriCon CorporationHeadquartered in Arden Hills,
Minn., IntriCon Corporation designs, develops and manufactures
miniature and micro-miniature body-worn devices. These advanced
products help medical, healthcare and professional communications
companies meet the rising demand for smaller, more intelligent and
better connected devices. IntriCon has facilities in the United
States, Asia and Europe. The company’s common stock trades under
the symbol “IIN” on the NASDAQ Global Market. For more information
about IntriCon, visit www.intricon.com.
Forward-Looking StatementsStatements made in this release
and in IntriCon’s other public filings and releases that are not
historical facts or that include forward-looking terminology are
“forward-looking statements” within the meaning of the Securities
Exchange Act of 1934, as amended. These forward-looking statements
may be affected by known and unknown risks, uncertainties and other
factors that are beyond IntriCon’s control, and may cause
IntriCon’s actual results, performance or achievements to differ
materially from the results, performance and achievements expressed
or implied in the forward-looking statements. These risks,
uncertainties and other factors are detailed from time to time in
the company’s filings with the Securities and Exchange Commission,
including the Annual Report on Form 10-K for the year ended
December 31, 2013. The company disclaims any intent or obligation
to publicly update or revise any forward-looking statements,
regardless of whether new information becomes available, future
developments occur or otherwise.
INTRICON CORPORATION Consolidated Condensed
Statements of Operations (In Thousands, Except Per Share
Amounts)
Three Months Ended Twelve Months Ended December 31, December
31, December 31, December 31, 2014 2013 2014 2013
(Unaudited)
(Unaudited)
(Unaudited)
(Unaudited)
Sales, net $ 16,481 $ 15,026 $ 68,303 $ 52,961 Cost of sales
12,018 11,189 49,819
40,792 Gross profit 4,463 3,837 18,484 12,169
Operating expenses: Sales and marketing 884 884 3,699 3,308 General
and administrative 1,575 1,350 6,462 5,789 Research and development
1,302 1,184 4,832 4,181 Restructuring charges -
30 83 229 Total operating
expenses 3,761 3,448 15,076
13,507 Operating income (loss) 702 389 3,408
(1,338 ) Interest expense (99 ) (132 ) (461 ) (600 ) Equity
in loss of partnerships (71 ) (78 ) (228 ) (262 ) Other income
(expense) 105 14 227
127 Income (loss) from continuing operations before
income taxes and discontinued operations 637 193 2,946 (2,073 )
Income tax expense 277 58
428 217 Income (loss) before discontinued
operations 360 135 2,518 (2,290 ) Loss on sale of discontinued
operations - - (120 ) - Loss from discontinued operations, net of
income taxes - (1,558 ) (150 )
(3,872 ) Net income (loss) $ 360 $ (1,423 ) $ 2,248 $
(6,162 ) Basic income (loss) per share: Continuing
operations $ 0.06 $ 0.02 $ 0.43 $ (0.40 ) Discontinued operations
- (0.27 ) (0.05 ) (0.68 ) Net
income (loss) per share: $ 0.06 $ (0.25 ) $ 0.39 $
(1.08 ) Diluted income (loss) per share: Continuing
operations $ 0.06 $ 0.02 $ 0.42 $ (0.40 ) Discontinued operations
- (0.27 ) (0.04 ) (0.68 ) Net
income (loss) per share: $ 0.06 $ (0.25 ) $ 0.37 $
(1.08 ) Average shares outstanding: Basic 5,831 5,710 5,791
5,699 Diluted 6,122 5,710 6,038 5,699
INTRICON
CORPORATION Consolidated Condensed Balance Sheets (In
Thousands, Except Per Share Amounts)
December 31, December 31,
2014
2013
Current assets: Cash $ 328 $ 217 Restricted cash 640 568 Accounts
receivable, less allowance for doubtful accounts of $120 at
December 31, 2014 and $124 at December 31, 2013 7,673 5,433
Inventories 9,983 9,400 Other current assets 1,013 1,337 Current
assets of discontinued operations - 382
Total current assets 19,637 17,337 Machinery and equipment
35,104 33,971 Less: Accumulated depreciation 30,859
29,232 Net machinery and equipment 4,245 4,739
Goodwill 9,194 9,194 Investment in partnerships 387 569 Other
assets, net 498 749 Other assets of discontinued operations
- 132 Total assets $ 33,961 $ 32,720
Current liabilities: Checks written in excess of cash
$ 516 $ 279 Current maturities of long-term debt 1,886 2,210
Accounts payable 5,438 5,037 Accrued salaries, wages and
commissions 2,519 1,676 Deferred gain 110 110 Other accrued
liabilities 1,364 1,893 Current liabilities of discontinued
operations - 154 Total current
liabilities 11,833 11,359 Long-term debt, less current
maturities 4,627 6,271 Other postretirement benefit obligations 485
531 Accrued pension liabilities 741 839 Deferred gain 55 165 Other
long-term liabilities 113 247 Total
liabilities 17,854 19,412 Commitments and contingencies
Shareholders’ equity: Common stock, $1.00 par value per share;
20,000 shares authorized; 5,844 and 5,727 shares issued and
outstanding at December 31, 2014 and December 31, 2013,
respectively 5,844 5,727 Additional paid-in capital 16,939 16,434
Accumulated deficit (6,274 ) (8,522 ) Accumulated other
comprehensive loss (402 ) (331 ) Total shareholders'
equity 16,107 13,308 Total liabilities
and shareholders’ equity $ 33,961 $ 32,720
At IntriCon:Scott Longval, CFO,
651-604-9526slongval@intricon.comorAt PadillaCRT:Matt
Sullivan, 612-455-1709matt.sullivan@padillacrt.com
Intricon (NASDAQ:IIN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intricon (NASDAQ:IIN)
Historical Stock Chart
From Apr 2023 to Apr 2024